Identiv Sees Q1 Revenue of $6.7M-$7.2M, Consensus at $5.17M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 12 2026
0mins
Should l Buy INVE?
Identiv sees Q1 revenue $6.7M-$7.2M, consensus $5.17M
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INVE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INVE
Wall Street analysts forecast INVE stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.790
Low
5.00
Averages
5.33
High
6.00
Current: 3.790
Low
5.00
Averages
5.33
High
6.00
About INVE
Identiv, Inc. is engaged in designing, producing, and selling radio-frequency identification (RFID) and Bluetooth Low Energy (BLE)-enabled devices. The Company’s full-circle RFID-enabled Internet of Things (IoT) solutions enable digital identities for physical objects, enhancing global connectivity for businesses, people, and the planet. Built into over 1.5 billion applications worldwide, its IoT solutions are suitable for a multitude of applications across a wide range of end markets, including healthcare, consumer electronics, luxury goods, smart packaging, logistics and warehouse tracking. The Company operates in the IoT Business segment. Its specialty RFID IoT devices are attached to or embedded into physical items, providing those items with a unique digital identity. Its offerings range from an IoT connecting cloud to advanced readers and cards, including active and passive BLE, near field communication (NFC), high frequency (HF), dual frequency (DF), and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Identiv Reports Q4 2025 Earnings Highlights
- Sales Performance Exceeds Expectations: Identiv reported $6.2 million in revenue for Q4 2025, surpassing guidance and reflecting a 24% increase from Q3's $5.0 million, although down 7.5% from $6.7 million in Q4 2024, indicating ongoing progress in its high-growth BLE strategy.
- Significant Margin Improvement: The successful transition to the new manufacturing facility in Thailand resulted in a non-GAAP gross margin of 25.6% for Q4, a substantial increase from negative 5.2% in the same quarter last year, highlighting enhanced cost control and production efficiency.
- Strong Cash Position: Identiv ended Q4 2025 with $128.9 million in cash and cash equivalents, a sequential increase of $2.3 million over Q3, demonstrating improved financial management and providing a solid foundation for future investments.
- Optimistic Outlook: Management anticipates Q1 2026 sales between $6.7 million and $7.2 million, representing a 26% to 35% increase over Q1 2025's $5.3 million, driven by new customer orders, while also noting potential short-term variability in gross margins during production scaling.
See More
Identive Set to Announce Q4 Earnings on March 12
- Earnings Announcement Date: Identive (INVE) is scheduled to release its Q4 earnings on March 12 after market close, with investors keenly awaiting the results to gauge the company's future prospects.
- Declining EPS Expectations: The consensus EPS estimate stands at -$0.14, reflecting a 27.3% year-over-year decline, indicating challenges in profitability that could impact investor confidence.
- Revenue Forecast Drop: The consensus revenue estimate is $5.65 million, down 15.7% year-over-year, suggesting that the company may face pressure in a competitive market and needs to implement strategies to regain growth.
- Historical Performance Review: Over the past two years, Identive has only beaten EPS estimates 13% of the time while surpassing revenue estimates 75% of the time, indicating relative stability in revenue but a need for improvement in profitability.
See More
Identiv Signs Exclusive Supply Agreement with IFCO for BLE Smart Labels
- Strategic Milestone: Identiv's exclusive supply agreement with IFCO establishes a significant partnership to provide next-generation BLE smart labels for over 400 million reusable packaging containers, reinforcing Identiv's leadership in the BLE smart label market.
- High-Volume Manufacturing Commitment: Under the agreement, Identiv will serve as the exclusive supplier, ensuring the production of millions of BLE labels to meet IFCO's needs in fresh food packaging, thereby enhancing the company's competitiveness in the rapidly growing IoT market.
- Global Network Integration: IFCO will integrate these customized BLE labels across its global network, expected to improve the efficiency of the fresh food supply chain, reduce costs and food waste, while enhancing sustainability efforts.
- Market Outlook: This agreement not only solidifies Identiv's leadership position in complex global industries but also lays the groundwork for future innovations and market expansion, driving continued growth in the IoT solutions sector.
See More
Identiv to Hold Q4 2025 Earnings Call on March 12, 2026
- Earnings Call Announcement: Identiv will hold a teleconference on March 12, 2026, at 5:00 PM EDT to discuss its financial results for Q4 and the fiscal year ending December 31, 2025, with results published beforehand for investor review.
- Teleconference Details: The call will feature toll-free and international dialing options, with a toll-free number at +1 888-506-0062 and an international number at +1 973-528-0011, ensuring global investor participation and access to the latest updates.
- Webcast Availability: The teleconference will also be webcast, allowing investors to register via a provided link to listen live or access a replay, enhancing information accessibility and transparency for stakeholders.
- Replay Information: The teleconference replay will be available until March 26, 2026, with investors able to dial +1 877-481-4010 or +1 919-882-2331 for playback, ensuring that those unable to attend live can still obtain critical insights.
See More
Identiv to Hold Q4 2025 Earnings Call on March 12, 2026
- Earnings Call Announcement: Identiv will hold a teleconference on March 12, 2026, at 5:00 PM EDT to discuss its financial results for Q4 and fiscal year 2025, which is expected to significantly impact investor sentiment.
- Financial Results Release: Prior to the call, a press release detailing the financial results will be published and made available on the company's investor relations website, ensuring timely access to critical information for informed decision-making.
- Teleconference Access Information: Investors can join the call by dialing +1 888-506-0062 for toll-free access or +1 973-528-0011 for international calls, using call ID 610948, facilitating smooth participation in the discussion and updates.
- Webcast and Replay Availability: The teleconference will also be webcast live, with a replay available until March 26, 2026, allowing investors who cannot attend the live session to access the information through +1 877-481-4010 for replay, ensuring comprehensive communication of the company's performance.
See More
Identiv Cold Chain Tracking Solution Wins 2025 IoT Platforms Leadership Award
- Industry Recognition: The cold chain tracking solution from Identiv and Tag-N-Trac has been awarded the 2025 IoT Platforms Leadership Award, highlighting its technological leadership in the IoT ecosystem and enhancing the company's competitive position in the pharmaceutical sector.
- Real-Time Monitoring Capability: This solution provides continuous real-time insights into the location, condition, and compliance of temperature-sensitive pharmaceuticals, significantly improving supply chain intelligence and enabling safer delivery of therapies.
- Innovative Architecture: With a modular, API-driven architecture, the system processes real-time data from IoT devices and aligns with the Drug Supply Chain Security Act (DSCSA), enhancing efficiency and responsiveness across global logistics networks.
- Customer Trust Assurance: Identiv's CEO emphasized that by transforming ambient data from the pharmaceutical supply chain into actionable intelligence, the solution not only simplifies deployment but also strengthens customer trust in drug safety, driving digital transformation in the industry.
See More
Identiv Reports Q4 2025 Earnings Highlights
- Sales Performance Exceeds Expectations: Identiv reported $6.2 million in revenue for Q4 2025, surpassing guidance and reflecting a 24% increase from Q3's $5.0 million, although down 7.5% from $6.7 million in Q4 2024, indicating ongoing progress in its high-growth BLE strategy.
- Significant Margin Improvement: The successful transition to the new manufacturing facility in Thailand resulted in a non-GAAP gross margin of 25.6% for Q4, a substantial increase from negative 5.2% in the same quarter last year, highlighting enhanced cost control and production efficiency.
- Strong Cash Position: Identiv ended Q4 2025 with $128.9 million in cash and cash equivalents, a sequential increase of $2.3 million over Q3, demonstrating improved financial management and providing a solid foundation for future investments.
- Optimistic Outlook: Management anticipates Q1 2026 sales between $6.7 million and $7.2 million, representing a 26% to 35% increase over Q1 2025's $5.3 million, driven by new customer orders, while also noting potential short-term variability in gross margins during production scaling.
See More
Identive Set to Announce Q4 Earnings on March 12
- Earnings Announcement Date: Identive (INVE) is scheduled to release its Q4 earnings on March 12 after market close, with investors keenly awaiting the results to gauge the company's future prospects.
- Declining EPS Expectations: The consensus EPS estimate stands at -$0.14, reflecting a 27.3% year-over-year decline, indicating challenges in profitability that could impact investor confidence.
- Revenue Forecast Drop: The consensus revenue estimate is $5.65 million, down 15.7% year-over-year, suggesting that the company may face pressure in a competitive market and needs to implement strategies to regain growth.
- Historical Performance Review: Over the past two years, Identive has only beaten EPS estimates 13% of the time while surpassing revenue estimates 75% of the time, indicating relative stability in revenue but a need for improvement in profitability.
See More
Identiv Signs Exclusive Supply Agreement with IFCO for BLE Smart Labels
- Strategic Milestone: Identiv's exclusive supply agreement with IFCO establishes a significant partnership to provide next-generation BLE smart labels for over 400 million reusable packaging containers, reinforcing Identiv's leadership in the BLE smart label market.
- High-Volume Manufacturing Commitment: Under the agreement, Identiv will serve as the exclusive supplier, ensuring the production of millions of BLE labels to meet IFCO's needs in fresh food packaging, thereby enhancing the company's competitiveness in the rapidly growing IoT market.
- Global Network Integration: IFCO will integrate these customized BLE labels across its global network, expected to improve the efficiency of the fresh food supply chain, reduce costs and food waste, while enhancing sustainability efforts.
- Market Outlook: This agreement not only solidifies Identiv's leadership position in complex global industries but also lays the groundwork for future innovations and market expansion, driving continued growth in the IoT solutions sector.
See More
Identiv to Hold Q4 2025 Earnings Call on March 12, 2026
- Earnings Call Announcement: Identiv will hold a teleconference on March 12, 2026, at 5:00 PM EDT to discuss its financial results for Q4 and the fiscal year ending December 31, 2025, with results published beforehand for investor review.
- Teleconference Details: The call will feature toll-free and international dialing options, with a toll-free number at +1 888-506-0062 and an international number at +1 973-528-0011, ensuring global investor participation and access to the latest updates.
- Webcast Availability: The teleconference will also be webcast, allowing investors to register via a provided link to listen live or access a replay, enhancing information accessibility and transparency for stakeholders.
- Replay Information: The teleconference replay will be available until March 26, 2026, with investors able to dial +1 877-481-4010 or +1 919-882-2331 for playback, ensuring that those unable to attend live can still obtain critical insights.
See More
Identiv to Hold Q4 2025 Earnings Call on March 12, 2026
- Earnings Call Announcement: Identiv will hold a teleconference on March 12, 2026, at 5:00 PM EDT to discuss its financial results for Q4 and fiscal year 2025, which is expected to significantly impact investor sentiment.
- Financial Results Release: Prior to the call, a press release detailing the financial results will be published and made available on the company's investor relations website, ensuring timely access to critical information for informed decision-making.
- Teleconference Access Information: Investors can join the call by dialing +1 888-506-0062 for toll-free access or +1 973-528-0011 for international calls, using call ID 610948, facilitating smooth participation in the discussion and updates.
- Webcast and Replay Availability: The teleconference will also be webcast live, with a replay available until March 26, 2026, allowing investors who cannot attend the live session to access the information through +1 877-481-4010 for replay, ensuring comprehensive communication of the company's performance.
See More
Identiv Cold Chain Tracking Solution Wins 2025 IoT Platforms Leadership Award
- Industry Recognition: The cold chain tracking solution from Identiv and Tag-N-Trac has been awarded the 2025 IoT Platforms Leadership Award, highlighting its technological leadership in the IoT ecosystem and enhancing the company's competitive position in the pharmaceutical sector.
- Real-Time Monitoring Capability: This solution provides continuous real-time insights into the location, condition, and compliance of temperature-sensitive pharmaceuticals, significantly improving supply chain intelligence and enabling safer delivery of therapies.
- Innovative Architecture: With a modular, API-driven architecture, the system processes real-time data from IoT devices and aligns with the Drug Supply Chain Security Act (DSCSA), enhancing efficiency and responsiveness across global logistics networks.
- Customer Trust Assurance: Identiv's CEO emphasized that by transforming ambient data from the pharmaceutical supply chain into actionable intelligence, the solution not only simplifies deployment but also strengthens customer trust in drug safety, driving digital transformation in the industry.
See More
